{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T13:13:42Z","timestamp":1784985222628,"version":"3.55.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013238","name":"Mahidol University Faculty of Medicine Siriraj Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013238","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004156","name":"Mahidol University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004704","name":"National Research Council of Thailand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004704","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.biopha.2025.118820","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T15:28:12Z","timestamp":1764084492000},"page":"118820","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Dual targeting of BCMA and B7-H3 with CAR T cells and bispecific protein engagers enhances anti-myeloma activity"],"prefix":"10.1016","volume":"193","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-7678-6732","authenticated-orcid":false,"given":"Naeramit","family":"Sontayananon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pornpimon","family":"Yuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1951-9948","authenticated-orcid":false,"given":"Nunghathai","family":"Sawasdee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8347-3000","authenticated-orcid":false,"given":"Mutita","family":"Junking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5459-8031","authenticated-orcid":false,"given":"Jatuporn","family":"Sujjitjoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pa-Thai","family":"Yenchitsomanus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9686","key":"10.1016\/j.biopha.2025.118820_bib1","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0140-6736(09)60221-X","article-title":"Multiple myeloma","volume":"374","author":"Raab","year":"2009","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.biopha.2025.118820_bib2","doi-asserted-by":"crossref","first-page":"e670","DOI":"10.1016\/S2352-3026(22)00165-X","article-title":"The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends","volume":"9","author":"Huang","year":"2022","journal-title":"Lancet Haematol."},{"issue":"4","key":"10.1016\/j.biopha.2025.118820_bib3","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/bmt.2015.307","article-title":"Evolving paradigms in the treatment of relapsed\/refractory multiple myeloma: increased options and increased complexity","volume":"51","author":"Cornell","year":"2016","journal-title":"Bone Marrow Transplant."},{"issue":"1","key":"10.1016\/j.biopha.2025.118820_bib4","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13045-021-01067-5","article-title":"CAR-T cells and BiTEs in solid tumors: challenges and perspectives","volume":"14","author":"Edeline","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118820_bib5","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1146\/annurev-med-060512-150254","article-title":"Chimeric antigen receptor therapy for cancer","volume":"65","author":"Barrett","year":"2014","journal-title":"Annu. Rev. Med."},{"issue":"1","key":"10.1016\/j.biopha.2025.118820_bib6","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1084\/jem.20031330","article-title":"BCMA is essential for the survival of long-lived bone marrow plasma cells","volume":"199","author":"O'Connor","year":"2004","journal-title":"J. Exp. Med."},{"issue":"5","key":"10.1016\/j.biopha.2025.118820_bib7","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.4049\/jimmunol.175.5.2814","article-title":"B cell maturation antigen, the receptor for a proliferation-inducing ligand and B cell-activating factor of the TNF family, induces antigen presentation in B cells","volume":"175","author":"Yang","year":"2005","journal-title":"J. Immunol."},{"issue":"11","key":"10.1016\/j.biopha.2025.118820_bib8","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.2217\/imt.15.77","article-title":"Targeting B-cell maturation antigen in multiple myeloma","volume":"7","author":"Tai","year":"2015","journal-title":"Immunotherapy"},{"issue":"2","key":"10.1016\/j.biopha.2025.118820_bib9","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1182\/blood-2003-06-2043","article-title":"Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival","volume":"103","author":"Novak","year":"2004","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.biopha.2025.118820_bib10","first-page":"3225","article-title":"APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment","volume":"127","author":"Tai","year":"2016","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"10.1016\/j.biopha.2025.118820_bib11","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.3389\/fimmu.2018.01821","article-title":"Targeting B cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy","volume":"9","author":"Cho","year":"2018","journal-title":"Front. Immunol."},{"issue":"14","key":"10.1016\/j.biopha.2025.118820_bib12","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1158\/1078-0432.CCR-24-0378","article-title":"FDA approval summary: ciltacabtagene autoleucel for relapsed or refractory multiple myeloma","volume":"30","author":"Natrajan","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.biopha.2025.118820_bib13","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.biopha.2025.118820_bib14","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.biopha.2025.118820_bib15","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"10301","key":"10.1016\/j.biopha.2025.118820_bib16","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","article-title":"Teclistamab, a B-cell maturation antigen\u00d7 CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study","volume":"398","author":"Usmani","year":"2021","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.biopha.2025.118820_bib17","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.biopha.2025.118820_bib18","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti\u2013B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2025.118820_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2023.12.016","article-title":"Safety and efficacy of teclistamab in patients with relapsed\/refractory multiple myeloma: a real-world experience","volume":"30","author":"Dima","year":"2024","journal-title":"Transplant. Cell. Ther."},{"issue":"22","key":"10.1016\/j.biopha.2025.118820_bib20","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T cells genetically modified to express an anti\u2013B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.biopha.2025.118820_bib21","first-page":"1688","article-title":"T cells expressing an anti\u2013B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"8","key":"10.1016\/j.biopha.2025.118820_bib22","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.clml.2017.06.014","article-title":"Immuno-oncologic approaches: CAR-T cells and checkpoint inhibitors","volume":"17","author":"Gay","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"4","key":"10.1016\/j.biopha.2025.118820_bib23","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008429","article-title":"PD-1 downregulation enhances CAR-T cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion","volume":"12","author":"Ouyang","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2025.118820_bib24","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13045-022-01364-7","article-title":"Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy","volume":"15","author":"Zhao","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"5","key":"10.1016\/j.biopha.2025.118820_bib25","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.str.2013.03.003","article-title":"Structure and T cell inhibition properties of B7 family member, B7-H3","volume":"21","author":"Vigdorovich","year":"2013","journal-title":"Structure"},{"issue":"7","key":"10.1016\/j.biopha.2025.118820_bib26","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/eji.200839028","article-title":"B7-H3 is a potent inhibitor of human T-cell activation: no evidence for B7-H3 and TREML2 interaction","volume":"39","author":"Leitner","year":"2009","journal-title":"Eur. J. Immunol."},{"issue":"14","key":"10.1016\/j.biopha.2025.118820_bib27","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1158\/1078-0432.CCR-15-2428","article-title":"Molecular pathways: targeting B7-H3 (CD276) for human cancer immunotherapy","volume":"22","author":"Picarda","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.biopha.2025.118820_bib28","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1186\/s12885-024-13061-4","article-title":"B7-H3 is widely expressed in soft tissue sarcomas","volume":"24","author":"Lynch","year":"2024","journal-title":"BMC Cancer"},{"issue":"11","key":"10.1016\/j.biopha.2025.118820_bib29","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1158\/1078-0432.CCR-17-2852","article-title":"B7-H3 negatively modulates CTL-mediated cancer immunity","volume":"24","author":"Yonesaka","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.biopha.2025.118820_bib30","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1038\/sj.bjc.6605375","article-title":"Clinical importance of B7-H3 expression in human pancreatic cancer","volume":"101","author":"Yamato","year":"2009","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2025.118820_bib31","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3892\/ijmm.2012.1212","article-title":"B7-H3 overexpression in pancreatic cancer promotes tumor progression","volume":"31","author":"Zhao","year":"2013","journal-title":"Int. J. Mol. Med."},{"issue":"7","key":"10.1016\/j.biopha.2025.118820_bib32","doi-asserted-by":"crossref","first-page":"809","DOI":"10.2217\/imt-2016-0001","article-title":"Immune checkpoint blockade in human cancer therapy: lung cancer and hematologic malignancies","volume":"8","author":"Janakiram","year":"2016","journal-title":"Immunotherapy"},{"issue":"5","key":"10.1016\/j.biopha.2025.118820_bib33","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1158\/2767-9764.CRC-23-0546","article-title":"Pan-cancer interrogation of B7-H3 (CD276) as an actionable therapeutic target across human malignancies","volume":"4","author":"Miller","year":"2024","journal-title":"Cancer Res. Commun."},{"issue":"6","key":"10.1016\/j.biopha.2025.118820_bib34","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/s41375-018-0331-6","article-title":"B7-H3 promotes multiple myeloma cell survival and proliferation by ROS-dependent activation of Src\/STAT3 and c-Cbl-mediated degradation of SOCS3","volume":"33","author":"Lin","year":"2019","journal-title":"Leukemia"},{"issue":"54","key":"10.1016\/j.biopha.2025.118820_bib35","doi-asserted-by":"crossref","first-page":"93156","DOI":"10.18632\/oncotarget.21114","article-title":"Prognostic value of B7-H3 expression in patients with solid tumors: a meta-analysis","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.biopha.2025.118820_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0183390","article-title":"Bispecific T cell engager (BiTE\u00ae) antibody constructs can mediate bystander tumor cell killing","volume":"12","author":"Ross","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.biopha.2025.118820_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115691","article-title":"Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myeloma","volume":"168","author":"Yuti","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.biopha.2025.118820_bib38","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s10238-024-01347-7","article-title":"Therapeutic potential of third-generation chimeric antigen receptor T cells targeting B cell maturation antigen for treating multiple myeloma","volume":"24","author":"Rujirachaivej","year":"2024","journal-title":"Clin. Exp. Med."},{"issue":"50","key":"10.1016\/j.biopha.2025.118820_bib39","doi-asserted-by":"crossref","first-page":"30018","DOI":"10.1074\/jbc.M115.679852","article-title":"Humanized affinity-matured monoclonal antibody 8H9 has potent antitumor activity and binds to FG loop of tumor antigen B7-H3","volume":"290","author":"Ahmed","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.biopha.2025.118820_bib40","doi-asserted-by":"crossref","first-page":"6938","DOI":"10.4049\/jimmunol.0901766","article-title":"The optimal antigen response of chimeric antigen receptors harboring the CD3\u03b6 transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR\/CD3 complex","volume":"184","author":"Bridgeman","year":"2010","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118820_bib41","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/cei.12216","article-title":"CD3\u03b6-based chimeric antigen receptors mediate T cell activation via cis-and trans-signalling mechanisms: implications for optimization of receptor structure for adoptive cell therapy","volume":"175","author":"Bridgeman","year":"2014","journal-title":"Clin. Exp. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118820_bib42","first-page":"72","article-title":"Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells","volume":"119","author":"Terakura","year":"2012","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"3","key":"10.1016\/j.biopha.2025.118820_bib43","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/icb.2014.93","article-title":"Bispecific T-cell engagers for cancer immunotherapy","volume":"93","author":"Huehls","year":"2015","journal-title":"Immunol. Cell Biol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118820_bib44","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1146\/annurev-immunol-042617-053352","article-title":"Signaling and function of interleukin-2 in T lymphocytes","volume":"36","author":"Ross","year":"2018","journal-title":"Annu. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.biopha.2025.118820_bib45","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005967","article-title":"Apoptosis: A Janus bifrons in T-cell immunotherapy","volume":"11","author":"Lee","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"7","key":"10.1016\/j.biopha.2025.118820_bib46","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies\u2014BiTEs and beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.biopha.2025.118820_bib47","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor antigen escape from CAR T-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.biopha.2025.118820_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100971","article-title":"GD2-specific chimeric antigen receptor-modified T cells targeting retinoblastoma\u2013assessing tumor and T cell interaction","volume":"14","author":"Sujjitjoon","year":"2021","journal-title":"Transl. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118820_bib49","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12967-024-05923-z","article-title":"Engineered T cells secreting \u03b1B7-H3-\u03b1CD3 bispecific engagers for enhanced anti-tumor activity against B7-H3 positive multiple myeloma: a novel therapeutic approach","volume":"23","author":"Rujirachaivej","year":"2025","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.biopha.2025.118820_bib50","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1038\/s41467-022-31430-0","article-title":"The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma","volume":"13","author":"Vo","year":"2022","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.biopha.2025.118820_bib51","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/bjh.12805","article-title":"The impact of intra-clonal heterogeneity on the treatment of multiple myeloma","volume":"165","author":"Brioli","year":"2014","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.biopha.2025.118820_bib52","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.3390\/ijms20051248","article-title":"The impact of tumor heterogeneity on diagnostics and novel therapeutic strategies in multiple myeloma","volume":"20","author":"Rasche","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.biopha.2025.118820_bib53","doi-asserted-by":"crossref","first-page":"8501","DOI":"10.3390\/curroncol30090619","article-title":"Bispecific T-cell engagers and chimeric antigen receptor T-cell therapies in glioblastoma: an update","volume":"30","author":"Alsajjan","year":"2023","journal-title":"Curr. Oncol."},{"issue":"4416","key":"10.1016\/j.biopha.2025.118820_bib54","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1126\/science.314668","article-title":"Monoclonal antibodies defining distinctive human T cell surface antigens","volume":"206","author":"Kung","year":"1979","journal-title":"Science"},{"key":"10.1016\/j.biopha.2025.118820_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-2776(08)60029-2","article-title":"Cell surface molecules and early events involved in human T lymphocyte activation","volume":"41","author":"Weiss","year":"1987","journal-title":"Adv. Immunol."},{"issue":"9","key":"10.1016\/j.biopha.2025.118820_bib56","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/s41587-019-0192-1","article-title":"CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity","volume":"37","author":"Choi","year":"2019","journal-title":"Nat. Biotechnol."},{"issue":"7","key":"10.1016\/j.biopha.2025.118820_bib57","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ymthe.2022.05.011","article-title":"Locally secreted BiTEs complement CAR T cells by enhancing killing of antigen heterogeneous solid tumors","volume":"30","author":"Yin","year":"2022","journal-title":"Mol. Ther."},{"issue":"10","key":"10.1016\/j.biopha.2025.118820_bib58","first-page":"1104","article-title":"T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals","volume":"140","author":"Philipp","year":"2022","journal-title":"Blood J. Am. Soc. Hematol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225010145?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225010145?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T07:08:10Z","timestamp":1777014490000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225010145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":58,"alternative-id":["S0753332225010145"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118820","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual targeting of BCMA and B7-H3 with CAR T cells and bispecific protein engagers enhances anti-myeloma activity","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118820","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118820"}}